Please select one: * I am in active clinical practice I am retired I am a student Other Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. * Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable 54321NA The skills learned in this CME course enhanced my professional competence. The skills learned in this CME course enhanced my professional competence. - 5 The skills learned in this CME course enhanced my professional competence. - 4 The skills learned in this CME course enhanced my professional competence. - 3 The skills learned in this CME course enhanced my professional competence. - 2 The skills learned in this CME course enhanced my professional competence. - 1 The skills learned in this CME course enhanced my professional competence. - NA The skills learned in this CME course will be applied in the treatment of my patients The skills learned in this CME course will be applied in the treatment of my patients - 5 The skills learned in this CME course will be applied in the treatment of my patients - 4 The skills learned in this CME course will be applied in the treatment of my patients - 3 The skills learned in this CME course will be applied in the treatment of my patients - 2 The skills learned in this CME course will be applied in the treatment of my patients - 1 The skills learned in this CME course will be applied in the treatment of my patients - NA How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? * Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied 54321 Identify potential and tradeoffs in MRI vs. PET for lesion delineation within the prostate during radiotherapy planning strategies. Identify potential and tradeoffs in MRI vs. PET for lesion delineation within the prostate during radiotherapy planning strategies. - 5 Identify potential and tradeoffs in MRI vs. PET for lesion delineation within the prostate during radiotherapy planning strategies. - 4 Identify potential and tradeoffs in MRI vs. PET for lesion delineation within the prostate during radiotherapy planning strategies. - 3 Identify potential and tradeoffs in MRI vs. PET for lesion delineation within the prostate during radiotherapy planning strategies. - 2 Identify potential and tradeoffs in MRI vs. PET for lesion delineation within the prostate during radiotherapy planning strategies. - 1 Describe potential options for toxicity reduction using anatomy-sparing SABR. Describe potential options for toxicity reduction using anatomy-sparing SABR. - 5 Describe potential options for toxicity reduction using anatomy-sparing SABR. - 4 Describe potential options for toxicity reduction using anatomy-sparing SABR. - 3 Describe potential options for toxicity reduction using anatomy-sparing SABR. - 2 Describe potential options for toxicity reduction using anatomy-sparing SABR. - 1 How confident are you in your ability to: * 5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice 54321 Apply metastasis-direct therapy on patients with oligometastatic gastrointestinal cancer? Apply metastasis-direct therapy on patients with oligometastatic gastrointestinal cancer? - 5 Apply metastasis-direct therapy on patients with oligometastatic gastrointestinal cancer? - 4 Apply metastasis-direct therapy on patients with oligometastatic gastrointestinal cancer? - 3 Apply metastasis-direct therapy on patients with oligometastatic gastrointestinal cancer? - 2 Apply metastasis-direct therapy on patients with oligometastatic gastrointestinal cancer? - 1 Execute clinical trials seeking to clarify the benefit of metastasis-directed therapy for patients with oligometastatic gastrointestinal cancer? Execute clinical trials seeking to clarify the benefit of metastasis-directed therapy for patients with oligometastatic gastrointestinal cancer? - 5 Execute clinical trials seeking to clarify the benefit of metastasis-directed therapy for patients with oligometastatic gastrointestinal cancer? - 4 Execute clinical trials seeking to clarify the benefit of metastasis-directed therapy for patients with oligometastatic gastrointestinal cancer? - 3 Execute clinical trials seeking to clarify the benefit of metastasis-directed therapy for patients with oligometastatic gastrointestinal cancer? - 2 Execute clinical trials seeking to clarify the benefit of metastasis-directed therapy for patients with oligometastatic gastrointestinal cancer? - 1 Was this course fair, balanced and without commercial bias? * Yes No If you checked "No,” please explain why: * What, if any, new skills/strategies will you apply in your clinical practice? * If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? Please provide any additional comments or suggestions. Name and ABS ID Required to claim MOC How did you hear about this course? * CME website Hospital-based Digital signage Pineapple Connect Email Google search Facebook LinkedIn Miami Medicine Journal CE Finder (CE Broker) CME Passport (ACCME) Other... How did you hear about this course? Other... Please select one: * M.D., D.O. Ph.D/Psy.D APRN/PA-C R.N. Sonographer Untrasound Tech Pharmacist Respiratory Other... Please select one: Other... Leave this field blank
